An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

@article{Buzdar2002AnOO,
  title={An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane},
  author={A. Buzdar and J. Robertson and W. Eiermann and J. Nabholtz},
  journal={Cancer},
  year={2002},
  volume={95}
}
  • A. Buzdar, J. Robertson, +1 author J. Nabholtz
  • Published 2002
  • Medicine
  • Cancer
  • The newer generation, nonsteroidal aromatase inhibitors (AIs) anastrozole and letrozole have shown superior efficacy compared with tamoxifen as first‐line treatments and compared with megestrol acetate as second‐line therapy in postmenopausal women with advanced breast carcinoma. In an open‐label, Phase II trial, it was reported that exemestane showed numerical superiority compared with tamoxifen for objective response and clinical benefit. Because these agents ultimately may be administered… CONTINUE READING
    219 Citations

    Topics from this paper.

    Aromatase inhibitors: a safety comparison
    • 14
    New aromatase inhibitors as second‐line endocrine therapy in postmenopausal patients with metastatic breast carcinoma
    • 31
    The adjuvant endocrine treatment revolution: focus on anastrozole
    • R. Jakesz
    • Medicine
    • Expert opinion on drug metabolism & toxicology
    • 2006
    • 2
    Long-term safety of aromatase inhibitors in the treatment of breast cancer
    • 40
    • Highly Influenced
    • PDF
    Are aromatase inhibitors superior to antiestrogens?
    • 28
    Data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial
    • A. Buzdar
    • Medicine
    • Clinical Cancer Research
    • 2004
    • 24
    Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males.
    • 57
    • PDF

    References

    SHOWING 1-10 OF 92 REFERENCES
    Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study.
    • 79
    • Highly Influential
    Risks and Benefits of Aromatase Inhibitors in Postmenopausal Breast Cancer
    • 34
    Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
    • A. Buzdar, W. Jonat, +8 authors P. Plourde
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1996
    • 390
    Exemestane in advanced breast cancer
    • 20
    Aromatase inhibitors in the treatment and prevention of breast cancer.
    • P. Goss, K. Strasser
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2001
    • 279
    Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.
    • 152
    ARIMIDEX™: A new oral, once-a-day aromatase inhibitor
    • 122
    Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
    • M. Dowsett, C. Pfister, +6 authors I. Smith
    • Medicine
    • Clinical cancer research : an official journal of the American Association for Cancer Research
    • 1999
    • 89
    • PDF